U.S. stocks rise on Fed cut bets; earnings continue to flow
Halozyme Therapeutics Inc. stock has reached an all-time high, trading at 76.34 USD. This milestone reflects a significant upward trend for the company, with a 27.6% gain over the past year and an impressive 58.5% return year-to-date. The company’s perfect Piotroski Score of 9, as reported by InvestingPro, indicates strong financial health. The biotech firm, known for its innovative drug delivery technology, has seen its shares steadily climb over the past year, driven by positive market sentiment and robust financial performance. With a market capitalization of $8.9 billion and strong revenue growth of 35%, this all-time high underscores investor confidence in Halozyme’s growth prospects and strategic initiatives. According to InvestingPro’s analysis, the stock currently shows upside potential based on its Fair Value calculations, with 15 additional exclusive insights available to subscribers.
In other recent news, Halozyme Therapeutics reported its second-quarter 2025 earnings, revealing a notable earnings per share (EPS) beat but a revenue miss. The company achieved an EPS of $1.54, exceeding the forecast of $1.24, but its revenue of $206 million fell short of the expected $286.01 million. Following the earnings report, Citizens JMP raised its price target for Halozyme to $91 from $78, citing the company’s financial results that surpassed both its and consensus estimates. Additionally, Halozyme raised its top-line and bottom-line guidance for 2025.
In another development, Goldman Sachs adjusted its price target for Halozyme to $56 from $55, maintaining a Neutral rating. This adjustment was based on potential impacts from upcoming CMS guidance on the Inflation Reduction Act. Meanwhile, Morgan Stanley upgraded Halozyme to Overweight from Equalweight, increasing its price target to $75 from $62. This upgrade was influenced by the passage of the ORPHAN Cures Act, which Morgan Stanley believes offers a positive outlook for Halozyme.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.